These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25895821)

  • 1. Advances in use of immunomodulatory agents--a rheumatology perspective.
    Her M; Kavanaugh A
    Nat Rev Gastroenterol Hepatol; 2015 Jun; 12(6):363-8. PubMed ID: 25895821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
    [No Abstract]   [Full Text] [Related]  

  • 4. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis.
    Tanaka Y
    Curr Opin Rheumatol; 2012 May; 24(3):319-26. PubMed ID: 22388646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological management of rheumatoid arthritis: the state of the art and the future perspective].
    Kameda H; Takeuchi T
    Nihon Rinsho; 2013 Jul; 71(7):1166-71. PubMed ID: 23961662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy.
    Valesini G; Montecucco C; Cutolo M
    Clin Exp Rheumatol; 2006; 24(4):413-23. PubMed ID: 16956432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Proposal for biologic drugs therapy in rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
    Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies in early rheumatoid arthritis.
    Smolen JS; Aletaha D; Machold KP
    Best Pract Res Clin Rheumatol; 2005 Feb; 19(1):163-77. PubMed ID: 15588977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative treatment strategies for patients with rheumatoid arthritis.
    van der Kooij SM; Allaart CF; Dijkmans BA; Breedveld FC
    Curr Opin Rheumatol; 2008 May; 20(3):287-94. PubMed ID: 18388520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of rheumatoid arthritis.
    Handa R
    Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF treatment in rheumatoid arthritis.
    Geiler J; Buch M; McDermott MF
    Curr Pharm Des; 2011; 17(29):3141-54. PubMed ID: 21864263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.